Research Analysts Offer Predictions for I-Mab Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for I-Mab to a loss of $0.08 per share from a previous loss estimate of $0.15, while maintaining a Buy rating and $9 price target.
• I-Mab reported a Q3 loss of $0.16 per share, and analysts project continued losses through 2030. The broader analyst consensus is Hold, with a $9.00 price target.
• I-Mab shares opened at $2.00, well below their one-year high of $6.79; institutional investors and hedge funds own 38.38% of the company, including a new 12,715-share position purchased by Brooklyn Investment Group.

I-Mab (NASDAQ:NBP - Free Report) - Research analysts at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for shares of I-Mab in a report released on Thursday, August 20th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.15). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for I-Mab's current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for I-Mab's Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.30) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.70) EPS, FY2029 earnings at ($0.59) EPS and FY2030 earnings at ($0.47) EPS.

I-Mab (NASDAQ:NBP - Get Free Report) last released its earnings results on Thursday, August 20th. The company reported ($0.16) earnings per share for the quarter.

Several other analysts also recently weighed in on NBP. Wall Street Zen raised shares of I-Mab from a "sell" rating to a "hold" rating in a research note on Saturday. Weiss Ratings upgraded shares of I-Mab from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $9.00.

I-Mab Price Performance

NBP stock opened at $2.00 on Monday. The stock has a market capitalization of $231.30 million, a P/E ratio of -5.56 and a beta of 1.47. I-Mab has a one year low of $1.46 and a one year high of $6.79. The business's 50 day simple moving average is $1.78.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in I-Mab stock. Brooklyn Investment Group bought a new stake in I-Mab (NASDAQ:NBP - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 12,715 shares of the company's stock, valued at approximately $51,000. 38.38% of the stock is currently owned by institutional investors and hedge funds.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source